Boehringer Ingelheim: Announced a broad agreement with the US government to reduce drug costs for American patients and expand its business layout in the US. It will invest $10 billion by 2028 to expand its pharmaceutical R&D and manufacturing business in the US.

Zhitongcaijing · 1d ago
Boehringer Ingelheim: Announced a broad agreement with the US government to reduce drug costs for American patients and expand its business layout in the US. It will invest $10 billion by 2028 to expand its pharmaceutical R&D and manufacturing business in the US.